IL248919A0 - Paediatric compositions for treating multiple sclerosis - Google Patents

Paediatric compositions for treating multiple sclerosis

Info

Publication number
IL248919A0
IL248919A0 IL248919A IL24891916A IL248919A0 IL 248919 A0 IL248919 A0 IL 248919A0 IL 248919 A IL248919 A IL 248919A IL 24891916 A IL24891916 A IL 24891916A IL 248919 A0 IL248919 A0 IL 248919A0
Authority
IL
Israel
Prior art keywords
multiple sclerosis
treating multiple
paediatric
compositions
paediatric compositions
Prior art date
Application number
IL248919A
Other languages
Hebrew (he)
Other versions
IL248919B (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40974366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL248919(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL248919A0 publication Critical patent/IL248919A0/en
Publication of IL248919B publication Critical patent/IL248919B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL248919A 2008-06-20 2016-11-13 Paediatric compositions for treating multiple sclerosis IL248919B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13262108P 2008-06-20 2008-06-20
PCT/US2009/047885 WO2009155475A1 (en) 2008-06-20 2009-06-19 Paediatric compositions for treating1 multiple sclerosis

Publications (2)

Publication Number Publication Date
IL248919A0 true IL248919A0 (en) 2017-01-31
IL248919B IL248919B (en) 2018-12-31

Family

ID=40974366

Family Applications (2)

Application Number Title Priority Date Filing Date
IL209725A IL209725A (en) 2008-06-20 2010-12-02 Paediatric compositions for treating multiple sclerosis
IL248919A IL248919B (en) 2008-06-20 2016-11-13 Paediatric compositions for treating multiple sclerosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL209725A IL209725A (en) 2008-06-20 2010-12-02 Paediatric compositions for treating multiple sclerosis

Country Status (16)

Country Link
US (11) US20110152380A1 (en)
EP (3) EP2303250A1 (en)
JP (7) JP2011525189A (en)
KR (4) KR20170081755A (en)
CN (2) CN104800196A (en)
BR (1) BRPI0914139A2 (en)
CA (1) CA2728514C (en)
CL (1) CL2010001463A1 (en)
IL (2) IL209725A (en)
MA (1) MA32480B1 (en)
MX (1) MX2010014223A (en)
NZ (1) NZ589618A (en)
RU (1) RU2562571C2 (en)
SG (1) SG10201406263SA (en)
WO (1) WO2009155475A1 (en)
ZA (1) ZA201008478B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170081755A (en) 2008-06-20 2017-07-12 노파르티스 아게 Paediatric compositions for treating multiple sclerosis
KR101393994B1 (en) * 2008-11-11 2014-05-14 노파르티스 아게 Crystalline forms of fingolimod hcl
HUE026869T2 (en) * 2008-12-22 2016-08-29 Novartis Ag Dosage regimen for fingolimod for the treatment of multiple sclerosis
SG178987A1 (en) 2009-09-29 2012-04-27 Novartis Ag Dosage regimen of an s1p receptor modulator
PE20140216A1 (en) 2011-01-07 2014-03-01 Novartis Ag IMMUNOSUPPRESSOR FORMULATIONS
MX2016001422A (en) * 2013-07-29 2016-10-05 Aizant Drug Res Solutions Pvt Ltd Pharmaceutical compositions of fingolimod.
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
DE122011100012I1 (en) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-amino-1,3-propanediol compound and immunosuppressant.
JP3745772B2 (en) 1993-12-17 2006-02-15 ノバルティス アクチエンゲゼルシャフト Rapamycin derivatives useful as immunosuppressants
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
DK0833828T3 (en) 1995-06-09 2003-03-17 Novartis Ag rapamycin derivatives
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
WO2000049008A1 (en) 1999-02-20 2000-08-24 Astrazeneca Ab Di- and tripeptide nitrile derivatives as inhibitors of cathepsin l and cathepsin s
EP1155010A1 (en) 1999-02-20 2001-11-21 AstraZeneca AB Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s
GB9903861D0 (en) 1999-02-20 1999-04-14 Zeneca Ltd Chemical compounds
US6395897B1 (en) 1999-03-02 2002-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5
GB9907683D0 (en) 1999-04-06 1999-05-26 Synphar Lab Inc Substituted azetidin-2-ones as cysteine protease inhibitors
EP1043027A1 (en) * 1999-04-08 2000-10-11 Applied Research Systems ARS Holding N.V. Treatment of multiple sclerosis with a combination of Interferon and Growth hormone
GB9911417D0 (en) 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
GB9917909D0 (en) 1999-07-31 1999-09-29 Synphar Lab Inc Cysteine protease inhibitors
ES2219388T3 (en) 1999-08-24 2004-12-01 Ariad Gene Therapeutics, Inc. 28-EPI-RAPALOGOS.
US6492362B1 (en) 1999-09-16 2002-12-10 Axys Pharmaceuticals, Inc. Compounds and compositions as cathepsin S inhibitors
GB9930449D0 (en) 1999-12-23 2000-02-16 Promotion & Display Tech Ltd Handset
CO5280088A1 (en) 2000-04-18 2003-05-30 Smithkline Beecham Corp PROTEASA INHIBITORS
ATE324372T1 (en) 2000-08-14 2006-05-15 Ortho Mcneil Pharm Inc SUBSTITUTED PYRAZOLES
WO2002014315A2 (en) 2000-08-14 2002-02-21 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
AU8125501A (en) 2000-08-14 2002-02-25 Ortho Mcneil Pharm Inc Substituted pyrazoles
US20040024000A1 (en) 2000-10-19 2004-02-05 Rajeshwar Singh Dihydropyrimidine derivatives as cysteine protease inhibitors
MXPA03005601A (en) 2000-12-22 2004-12-02 Axys Pharm Inc Novel compounds and compositions as cathepsin inhibitors.
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
US6900237B2 (en) 2001-09-14 2005-05-31 Axys Pharmaceuticals, Inc. Sulfonamide compounds as protease inhibitors
CN1324008C (en) 2001-09-14 2007-07-04 安万特药物公司 Novel compounds and compositions as cathepsin inhibitors
EP1434769A2 (en) 2001-10-02 2004-07-07 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cysteine proteases
WO2003037892A1 (en) 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
WO2003041649A2 (en) 2001-11-13 2003-05-22 Merck Frosst Canada & Co. Cyanoalkylamino derivatives as protease inhibitors
WO2003042197A1 (en) 2001-11-14 2003-05-22 Aventis Pharmaceuticals Inc. Oligopeptides and compositions containing them as cathepsin s inhibitors
EP1389480A1 (en) * 2002-08-14 2004-02-18 Mondobiotech Interferon SA Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation
TWI376363B (en) * 2002-09-24 2012-11-11 Novartis Ag Pharmaceutical combination for treating demyelinating disease
PE20130200A1 (en) 2003-04-08 2013-03-09 Novartis Ag PHARMACEUTICAL COMPOSITION CONTAINING AN S1P RECEPTOR AGONIST AND A SUGAR ALCOHOL
WO2004094653A2 (en) * 2003-04-22 2004-11-04 Irm Llc Differential tag length analysis of cell proliferation
JP4861177B2 (en) * 2003-09-12 2012-01-25 ニューロノバ エービー Treatment of nervous system disorders
GT200600350A (en) * 2005-08-09 2007-03-28 LIQUID FORMULATIONS
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
PL3103448T3 (en) 2006-09-26 2019-12-31 Novartis Ag Pharmaceutical compositions comprising an s1p modulator
KR20170081755A (en) 2008-06-20 2017-07-12 노파르티스 아게 Paediatric compositions for treating multiple sclerosis

Also Published As

Publication number Publication date
EP3011958A1 (en) 2016-04-27
CN104800196A (en) 2015-07-29
MA32480B1 (en) 2011-07-03
CN102076335A (en) 2011-05-25
IL209725A (en) 2016-11-30
JP2011525189A (en) 2011-09-15
US20130230489A1 (en) 2013-09-05
JP2023153786A (en) 2023-10-18
RU2011101771A (en) 2012-07-27
KR20160131126A (en) 2016-11-15
KR20170081755A (en) 2017-07-12
AU2009259950A1 (en) 2009-12-23
BRPI0914139A2 (en) 2015-10-20
JP2020063269A (en) 2020-04-23
NZ589618A (en) 2012-09-28
KR20110020928A (en) 2011-03-03
US20210023027A1 (en) 2021-01-28
EP2303250A1 (en) 2011-04-06
JP2018184424A (en) 2018-11-22
JP2021152016A (en) 2021-09-30
US20190117593A1 (en) 2019-04-25
US20180177747A1 (en) 2018-06-28
MX2010014223A (en) 2011-01-21
KR20180017232A (en) 2018-02-20
US20160206574A1 (en) 2016-07-21
CL2010001463A1 (en) 2011-05-06
US20190358178A1 (en) 2019-11-28
JP2017122106A (en) 2017-07-13
US20200197334A1 (en) 2020-06-25
US20170333368A1 (en) 2017-11-23
US20160022611A1 (en) 2016-01-28
IL248919B (en) 2018-12-31
IL209725A0 (en) 2011-02-28
CA2728514C (en) 2020-08-11
US20170128389A1 (en) 2017-05-11
EP3545953A1 (en) 2019-10-02
JP2015107984A (en) 2015-06-11
US20110152380A1 (en) 2011-06-23
WO2009155475A1 (en) 2009-12-23
ZA201008478B (en) 2012-01-25
RU2562571C2 (en) 2015-09-10
CA2728514A1 (en) 2009-12-23
SG10201406263SA (en) 2015-02-27

Similar Documents

Publication Publication Date Title
IL266189A (en) Methods for treating progressive multiple sclerosis
HK1139204A1 (en) Compositions and uses for treating multiple sclerosis
EP2282719A4 (en) Compositions and methods for treating multiple sclerosis
EP2355660A4 (en) Compositions and methods for treating multiple sclerosis
IL248919B (en) Paediatric compositions for treating multiple sclerosis
SI2205720T1 (en) Compositions for treating multiple sclerosis
PL2283101T3 (en) Hydrofluoroolefin compositions
PL2283102T3 (en) Hydrofluoroolefin compositions
GB0808835D0 (en) Therapeutic compositions
EP2368559A4 (en) Composition for preventing or treating artherosclerosis
HK1154797A1 (en) Composition for treating disease
GB0819958D0 (en) Therapeutic compositions
EP2174956A4 (en) Compositions for anti-fibrinolitic treatment
HK1159997A1 (en) Colostrum composition
GB0920151D0 (en) Contrast agent compositions
PL384259A1 (en) Pharmaceutical composition for treating skin-diseases
IL210519A0 (en) Anti-phthiraptera treatment compositions
GB0614058D0 (en) Treatment for multiple sclerosis
GB0722030D0 (en) Compositions for treating tumours
PL2341937T3 (en) Composition for treating disease
GB0800412D0 (en) Compositions
GB0805099D0 (en) Claening compositions